Altre lingue Liquidia Corporation

Azioni

LQDA

US53635D2027

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
12,28 ^USD	-2,54%		-1,92%	+2,08%

03/06	Il lancio di Yutrepia di Liquidia è stato autorizzato dal Tribunale che ha negato l'ingiunzione	MT
03/06	Il Tribunale distrettuale emette una sentenza favorevole e respinge la richiesta di United Therapeutics? la richiesta di bloccare il lancio di YUTREPIA? Lancio	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension	19/06
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)	18/06
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction	03/06
Liquidia Shares Jump on Latest Favorable Court Ruling for Yutrepia	03/06
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch	03/06
District Court Issues Favorable Ruling and Denies United Therapeutics? Request to Block YUTREPIA? Launch	03/06
Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference	29/05
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update	13/05
Liquidia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Liquidia Announces Poster Presentation at the American Thoracic Society 2024 International Conference on Its Open-Label Safety Study of L606 in Patients with PAH and PH-ILD	13/05
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD	10/05
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024	07/05
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024	07/05
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024	07/05
Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024	07/05
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	02/04
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference	02/04
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension	01/04
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling	01/04
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder	01/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Liquidia Corporation

Azioni

LQDA

US53635D2027

Altre lingue

Filtri